Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
ALLO Stock Chart & Stats
$2.39
-$0.03(-1.28%)
At close: 4:00 PM EST
$2.39
-$0.03(-1.28%)
Day’s Range― - ―
52-Week Range$0.98 - $4.46
Previous CloseN/A
Volume1.66M
Average Volume (3M)13.82M
Market Cap
$690.31M
Enterprise Value$538.48M
Total Cash (Recent Filing)$266.89M
Total Debt (Recent Filing)$81.05M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding345,154,570
10 Day Avg. Volume6,501,907
30 Day Avg. Volume13,821,130
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.52
Enterprise Value/Ebitda-3.20
Forecast
1Y Price Target
$8.71Price Target Upside264.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$13.85K
Bulls Say, Bears Say
Bulls Say
Commercial Outlook And Analyst ConfidenceAnalyst increases in approval probability, expected market penetration, and valuation, together with a reiterated Buy, reflect confidence that cema‑cel could capture a sizable commercial opportunity if approvals are received and manufacturing scales.
Efficacy - MRD ConversionHigher rates of minimal residual disease (MRD) negativity in the ALPHA3 trial reduce the risk of missing the primary event‑free survival endpoint and suggest a greater chance of meaningful clinical benefit.
Safety And TolerabilityReported absence of severe cytokine release syndrome, neurotoxicity, graft‑versus‑host disease, and serious infections for cema‑cel supports a favorable safety profile that could enable broader use in community cancer centers.
Bears Say
Durability RiskRisk that the therapy’s clinical benefit may not be durable could undermine long‑term value even if early MRD and ctDNA responses appear strong.
Financing And DilutionA planned public offering of common stock would raise cash but may dilute existing shareholders and pressure near‑term capital structure and share performance.
Regulatory And Timeline RiskRegulators requesting additional progression‑based data or more events for approval could delay timelines and postpone commercialization milestones.
Allogene Therapeutics News
ALLO FAQ
What was Allogene Therapeutics’s price range in the past 12 months?
Allogene Therapeutics lowest stock price was $0.98 and its highest was $4.46 in the past 12 months.
What is Allogene Therapeutics’s market cap?
Allogene Therapeutics’s market cap is $690.31M.
When is Allogene Therapeutics’s upcoming earnings report date?
Allogene Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 71 days.
How were Allogene Therapeutics’s earnings last quarter?
Allogene Therapeutics released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.
Is Allogene Therapeutics overvalued?
According to Wall Street analysts Allogene Therapeutics’s price is currently Undervalued.
Does Allogene Therapeutics pay dividends?
Allogene Therapeutics does not currently pay dividends.
What is Allogene Therapeutics’s EPS estimate?
Allogene Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Allogene Therapeutics have?
Allogene Therapeutics has 345,154,570 shares outstanding.
What happened to Allogene Therapeutics’s price movement after its last earnings report?
Allogene Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -8.155%.
Which hedge fund is a major shareholder of Allogene Therapeutics?
Currently, no hedge funds are holding shares in ALLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allogene Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.71 (264.59% Upside)
$8.71 (264.59% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 135.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.48%
12-Months-Change
Fundamentals
Return on Equity
-56.45%
Trailing 12-Months
Asset Growth
-22.05%
Trailing 12-Months
Company Description
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.View all ALLO earnings summariesALLO Stock 12 Month Forecast
Average Price Target
$8.71
▲(264.59% Upside)
Technical Analysis
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Tenaya Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
6.67% Insiders
7.95% Mutual Funds
23.39% Other Institutional Investors
54.13% Public Companies and
Individual Investors